You are here

Epi-seq: Multiplexed ChIP-seq for personalized medicine and drug discovery

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44HG010237-01
Agency Tracking Number: R44HG010237
Amount: $279,395.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 172
Solicitation Number: PAR16-016
Timeline
Solicitation Year: 2016
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-24
Award End Date (Contract End Date): 2019-04-30
Small Business Information
1914 PALOMAR OAKS STE 150
Carlsbad, CA 92008-6509
United States
DUNS: 109145701
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARY JELINEK
 (760) 431-1263
 mjelinek@activemotif.com
Business Contact
 THEODORE DEFRANK
Phone: (760) 431-1263
Email: defrank@activemotif.com
Research Institution
N/A
Abstract

SUMMARY
Dysregulation of epigenetic mechanisms is known to play important roles in the development and progression
several disease states including cancerautoimmuneneurological and inflammatory disordersIn cancer alonehigh frequency mutations in sixty epigenetic regulatory proteins have been identifiedLike
genome sequencingepigenetic information can be elucidated across the entire genome and profiling can be
used to find epigenetic abnormalities that cause or correlate with diseaseComputational integration of
genome wide genetic and epigenetic profilesepi genotypinghas enabled identification of novel disease
subgroupswith pediatric neuro oncology being a notable exampleDeveloping a systems solution that
facilitates integration of epigenetic data sets is key to enabling personalized medicine solutions for pathologies
with epigenetic dependenciesChromatin immunoprecipitationChIPis the primary method for genome wide
mapping of DNA associated proteinsIn contrast to the tremendous advances in DNA sequencing
technologieswhich are approaching the $genomeChIP has only had incremental improvements in
work flowreduction of background and sample size requirementsThis SBIR Fast Track proposal intends to
develop Epi Seqa high throughput multiplexing ChIP Seq platform to map functional alterations in the
epigenome on a scale and time frame suitable for clinical and drug screening applicationsWith automation
compatibility in mindEpi Seq combines sample preparation and solubilization of fixed chromatin using PIXULawell plate sonicator capable of shearingchromatin samples in less thanminuteswith TransposaseAssisted Multiplex ChIP SeqTAM ChIPto functionally annotate the entire genome in a high throughput
formatMultiplexing is achieved with a panel of recombinant AbFlexChIP qualified antibodies targeting
various hallmark features of the epigenetic landscapeeach of which has been conjugated to a transposasecompatible barcoded oligonucleotide via site directed conjugationPhase I feasibility will use PIXUL from
human and mouse tissues in Aimand compare TAM ChIP enabled AbFlexantibodies for key DNA binding
proteins and histone PTMs in traditional and TAM ChIP seq methodsPhase II product development efforts will
optimize TAM ChIP target multiplexing in Aimand Aimefforts will adapt current workflows for automation
compatibility such that a hands freesample to sequenceworkflow is achievedPhase II efforts will conclude
with alpha testing by independent laboratories whose feedback will be integrated into subsequent
commercialization efforts by Active MotifEpi Seq is an enabling technology with potential accelerate
development of epigenetic diagnosticsprognostic and therapeutics for diverse human pathologies and will be
offered both as a contract service and as a productsold independently or bundled with the PIXUL instrument ChIPchromatin immunoprecipitationis the keystone method for epigeneticsdefined as
regulatory mechanisms which affect heritable changes in cellular phenotypes independent of
DNA sequenceThis SBIR Fast Track proposal describes development of Epi seqan
automation compatible systems solution which streamlines ChIPenabling simultaneous
interrogation of multiple targets and provides for integration of complex bioinformatic datasetsThis technology will simplify epigeneticsand will accelerate its adoption in drug discovery and
personalized medicine

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government